<DOC>
	<DOCNO>NCT01921920</DOCNO>
	<brief_summary>This An Open-label , Randomized , Single-center , 4-way Crossover , Single dose Bioequivalence Study Comparing Omeprazole 20 40-mg Aqueous solvent Based Capsules Manufactured AstraZeneca Omeprazole 20 40-mg Organic-solvent Based Capsules Manufactured Merck</brief_summary>
	<brief_title>Prilosec Bioequivalence Study Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Healthy male female volunteer age 18 50 year , inclusive , suitable vein cannulation repeat venepuncture . Female could nonchildbearing potential ( postmenopausal irreversible surgical sterilization ) childbearing potential ( negative pregnancy test screening use 2 effective method avoid pregnancy ) . Have body mass index ( BMI ) 18 30 kg/m2 , inclusive , weight least 50 kg 100 kg , inclusive . History clinically important disease disorder , opinion Investigator , may either put volunteer risk participation study . History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration investigational medicinal product ( IMP ) . Any clinically significant abnormality physical examination , clinical laboratory value , 12lead ECG , vital sign , judge Investigator . Moderate heavy smoker ( 10 cigarette per day equivalent tobaccocontaining product ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Omeprazole , Prilosec , Phase I , Healthy Subjects , Pharmacokinetics , Bioequivalence</keyword>
</DOC>